Role of IFN-λs, IFN-λs related genes and the DEPDC5 gene in Hepatitis B virus-related liver disease

Journal of Viral Hepatitis

Volumn 21, Issue 7, 2014, Pages

  Ma, N ^a   Zhang, X ^a   Yu, F ^a   Gao, P ^a   Fan, Q ^b   Liu, L ^a   Liu, D ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Neurosurgery   (China)

Author keywords

DEPDC5; HBV; IFN s; IL10RB; PAPL; Polymorphisms

Indexed keywords

INTERLEUKIN 10 RECEPTOR BETA; P21 ACTIVATED KINASE 4; DEPDC5 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; INTERFERON; INTERLEUKIN DERIVATIVE; REPRESSOR PROTEIN;

ALCOHOL CONSUMPTION; ARTICLE; CODOMINANCE; CONTROLLED STUDY; DEP DOMAIN CONTAINING 5 GENE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAN CHINESE; HEPATITIS B; HEREDITY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INTERFERON LAMBDA GENE; INTERLEUKIN 10 RECEPTOR BETA GENE; INTERLEUKIN 28 RECEPTOR ALPHA GENE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; P21 ACTIVATED KINASE 4 GENE; PRIORITY JOURNAL; PURPLE ACID PHOSPHATASE LIKE PROTEIN GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO CONSUMPTION; VIRAL CLEARANCE; ADULT; AGED; CASE CONTROL STUDY; CHINA; FEMALE; GENETICS; GENOTYPING TECHNIQUE; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MASS SPECTROMETRY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; FEMALE; GENOTYPING TECHNIQUES; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; REPRESSOR PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84902268234     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12235     Document Type: Article

References (41)

1. Thursz M,. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001a; 52 (2): 113-116.
2. Thursz M,. MHC and the viral hepatitides. QJM 2001b; 94 (6): 287-291.
3. Chang HY, Ahn SH, Kim DY, et al,. Association between CCR5 promoter polymorphisms and hepatitis B virus infection. Korean J Hepatol 2005; 11 (2): 116-124.
4. Kummee P, Tangkijvanich P, Poovorawan Y, et al,. Association of HLA-DRB113 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat 2007; 14 (12): 841-848.
5. Zheng L, Li D, Wang F, et al,. Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. J Clin Immunol 2010; 30 (6): 855-860.
6. Thio CL, Mosbruger TL, Kaslow RA, et al,. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004; 78 (20): 11258-11262.
7. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10): 1105-1109.
8. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
9. Ank N, Paludan SR,. Type III IFNs: new layers of complexity in innate antiviral immunity. BioFactors 2009; 35 (1): 82-87.
10. Kawai T, Akira S,. Innate immune recognition of viral infection. Nat Immunol 2006; 7 (2): 131-137.
11. Kiu H, Nicholson SE,. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012; 30 (2): 88-106.
12. Zhang L, Jilg N, Shao RX, et al,. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2011; 55 (2): 289-298.
13. Cui Q, Zhang YX, Su J, et al,. Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect Genet Evol 2011; 11 (7): 1682-1689.
14. Chae SC, Park YR, Li CS, et al,. Analysis of the variations in IL-28RA gene and their association with allergic rhinitis. Exp Mol Med 2006; 38 (3): 302-309.
15. Gong QM, Kong XF, Yang ZT, et al,. Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. J Viral Hepat 2009; 16 (9): 674-680.
16. Hou J, Lin L, Zhou W, et al,. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19 (2): 232-243.
17. Oddie GW, Schenk G, Angel NZ, et al,. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone 2000; 27 (5): 575-584.
18. Miki D, Ochi H, Hayes CN, et al,. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011; 43 (8): 797-800.
19. Seng TJ, Ichimura K, Liu L, Tingby O, Pearson DM, Collins VP,. Complex chromosome 22 rearrangements in astrocytic tumors identified using microsatellite and chromosome 22 tile path array analysis. Genes Chromosom Cancer 2005; 43 (2): 181-193.
20. Kharrat A, Millevoi S, Baraldi E, Ponting CP, Bork P, Pastore A,. Conformational stability studies of the pleckstrin DEP domain: definition of the domain boundaries. Biochim Biophys Acta 1998; 1385 (1): 157-164.
21. Harada Y, Kanehira M, Fujisawa Y, et al,. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res 2010; 70 (14): 5829-5839.
22. Kanehira M, Harada Y, Takata R, et al,. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 2007; 26 (44): 6448-6455.
23. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5): 1208-1236.
24. El-Serag HB, Marrero JA, Rudolph L, et al,. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134 (6): 1752-1763.
25. Barrett JC, Fry B, Maller J, Daly MJ,. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 (2): 263-265.
26. Li W, Jiang Y, Jin Q, et al,. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011; 31 (8): 1118-1126.
27. Jiao XL, Gao YT, Jing L, et al,. Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection. Zhonghua Liu Xing Bing Xue Za Zhi 2011; 32 (11): 1143-1147.
28. Martin MP, Qi Y, Goedert JJ, et al,. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202 (11): 1749-1753.
29. Fabris C, Falleti E, Cussigh A, et al,. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 2011; 54 (4): 716-722.
30. Guidotti LG, Morris A, Mendez H, et al,. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002; 76 (6): 2617-2621.
31. Robek MD, Boyd BS, Chisari FV,. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79 (6): 3851-3854.
32. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10): 1100-1104.
33. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138 (4): 1338-45, 1345.e1-7.
34. Morrow MP, Pankhong P, Laddy DJ, et al,. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113 (23): 5868-5877.
35. Marcello T, Grakoui A, Barba-Spaeth G, et al,. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131 (6): 1887-1898.
36. Hong SH, Cho O, Kim K, et al,. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 2007; 126 (1-2): 245-249.
37. Pagliaccetti NE, Chu EN, Bolen CR, et al,. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 2010; 401 (2): 197-206.
38. Al-Qahtani AA, Al-Anazi RM, Abdo AA, et al,. Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. Liver international, [online] Available at: http://onlinelibrary.wiley.com/doi/10.1111/liv.12347/abstract? deniedAccessCustomisedMessage=&userIsAuthenticated=false (accessed 20 November 2013).
39. Sheppard P, Kindsvogel W, Xu W, et al,. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4 (1): 63-68.
40. Truelove AL, Oleksyk TK, Shrestha S, et al,. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet 2008; 35 (3): 255-264.
41. Ura S, Honda M, Yamashita T, et al,. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009; 49 (4): 1098-1112.